125 related articles for article (PubMed ID: 12360978)
21. Regarding the loss of CD20 after rituximab therapy.
Lee R; Braylan RC
Br J Haematol; 2002 Sep; 118(3):927. PubMed ID: 12181075
[No Abstract] [Full Text] [Related]
22. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
23. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia.
Stamatopoulos K; Papadaki T; Pontikoglou C; Athanasiadou I; Stavroyianni N; Bux J; Batsis I; Pyrovolaki K; Paterakis G; Anagnostou D; Anagnostopoulos A; Papadaki HA
Leukemia; 2008 Jul; 22(7):1446-9. PubMed ID: 18185527
[No Abstract] [Full Text] [Related]
24. Monoclonal antibody therapy in lymphoid malignancies.
Hainsworth JD
Oncologist; 2000; 5(5):376-84. PubMed ID: 11040273
[TBL] [Abstract][Full Text] [Related]
25. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
26. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma.
Scott SD
Cancer Pract; 1998; 6(3):195-7. PubMed ID: 9652253
[TBL] [Abstract][Full Text] [Related]
27. Refractory cold agglutinin-immunohaemolytic anaemia associated to marginal zone lymphoma responding to rituximab.
Petit J; Clavo M; de Sevilla AF; González-Barca E; Domingo-Doménech E; Grañena A
Hematol J; 2003; 4(6):450-1. PubMed ID: 14671620
[TBL] [Abstract][Full Text] [Related]
28. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
Rastetter W; Molina A; White CA
Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532
[TBL] [Abstract][Full Text] [Related]
29. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Jabr FI
Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
[TBL] [Abstract][Full Text] [Related]
30. [Minimal residual disease in leukemia and lymphoma: biological significance and clinical applications].
Gavosto F; Saglìo G; Foà R
Haematologica; 1989 Oct; 74(5 Suppl):85-95. PubMed ID: 2512235
[No Abstract] [Full Text] [Related]
31. Infusion of rituximab over 90 minutes on an out-patient basis is safe and improves resource utilization.
El-Agnaf MR; McCoy C; Ong YL; Eswedi AH; Black B; Ramadan KM
Leuk Lymphoma; 2007 Sep; 48(9):1875-7. PubMed ID: 17786730
[No Abstract] [Full Text] [Related]
32. Severe pulmonary complications after initial treatment with Rituximab for the Asian-variant of intravascular lymphoma.
Wu SJ; Chou WC; Ko BS; Tien HF
Haematologica; 2007 Jan; 92(1):141-2. PubMed ID: 17229654
[TBL] [Abstract][Full Text] [Related]
33. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma.
Lossos IS; Morgensztern D; Blaya M; Alencar A; Pereira D; Rosenblatt J
Leuk Lymphoma; 2007 Aug; 48(8):1630-2. PubMed ID: 17701596
[No Abstract] [Full Text] [Related]
34. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.
Stel AJ; Ten Cate B; Jacobs S; Kok JW; Spierings DC; Dondorff M; Helfrich W; Kluin-Nelemans HC; de Leij LF; Withoff S; Kroesen BJ
J Immunol; 2007 Feb; 178(4):2287-95. PubMed ID: 17277134
[TBL] [Abstract][Full Text] [Related]
35. [Antibody therapy in hematology and oncology - part 1].
Kneba M; Schrader C; Köhne H
Med Klin (Munich); 2008 Dec; 103(12):843-59. PubMed ID: 19099214
[No Abstract] [Full Text] [Related]
36. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
Vega MI; Martínez-Paniagua M; Huerta-Yepez S; González-Bonilla C; Uematsu N; Bonavida B
Int J Oncol; 2009 Dec; 35(6):1289-96. PubMed ID: 19885551
[TBL] [Abstract][Full Text] [Related]
37. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.
Stolz C; Hess G; Hähnel PS; Grabellus F; Hoffarth S; Schmid KW; Schuler M
Blood; 2008 Oct; 112(8):3312-21. PubMed ID: 18689543
[TBL] [Abstract][Full Text] [Related]
38. [Ten years since the successful introduction of the first monoclonal antibody (rituximab) into the therapy of lymphomas].
Trnený M; Klener P
Cas Lek Cesk; 2007; 146(7):578-85. PubMed ID: 17722844
[TBL] [Abstract][Full Text] [Related]
39. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
[TBL] [Abstract][Full Text] [Related]
40. Rituximab.
Onrust SV; Lamb HM; Balfour JA
Drugs; 1999 Jul; 58(1):79-88; discussion 89-90. PubMed ID: 10439931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
